The September edition of SLAS Discovery is a Special Collection featuring the cover article, “Applications of Biophysics in Early Drug Discovery” by Geoffrey A. Holdgate (AstraZeneca, Macclesfield, UK) and Christian Bergsdorf, Ph.D. (Novartis Institutes for Biomedical Research, Basel, Switzerland).
Stem cell models derived from people with specific genomic variation recapitulate aspects of their autism spectrum disorder, providing a valuable model to study the condition and look for therapeutic interventions.
An untapped trove of desirable drug-like molecules is hidden in the genomes of Streptomyces bacteria — the same bacteria responsible for the first bacterial antibiotics to treat tuberculosis back in the 1940s. Isolating them, however, has proved challenging. Now, biologists at Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be “silencing” Streptomyces and preventing it from producing desirable compounds encoded by its genes.
The August edition of SLAS Discovery is a Special Collection featuring the cover article, “Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery” by Jayme L. Dahlin, M.D., Ph.D. (Brigham and Women’s Hospital, Boston, MA, USA).
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
Scientists at Oak Ridge National Laboratory and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in medicine, industry and agriculture.
UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
The July edition of SLAS Discovery is a Special Edition featuring the cover article, “Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry” by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).
Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.
Scientists have published the first detailed atomic-level model of the SARS-CoV-2 “envelope” protein bound to a human protein essential for maintaining the lining of the lungs. The findings may speed the search for drugs to block the most severe effects of COVID-19.
The June edition of SLAS Discovery features the cover article, “A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities” by Florian David, Ph.D. (Chalmers University of Technology, Gothenburg, Sweden), Andrew M. Davis, Ph.D. (AstraZeneca, Cambridge, England, UK). Michael Gossing, Ph.D., Martin A. Hayes, Ph.D., and Elvira Romero, Ph.D., and Louis H. Scott, Ph.D. (AstraZeneca, Gothenburg, Sweden), and Mark J. Wigglesworth, Ph.D. (AstraZeneca, London, England, UK).
Researchers have developed first-in-class small-molecule inhibitors against a key leukemia protein, ASH1L.
New Brunswick, N.J. (March 3, 2021) – The 3D structures of more than 1,000 SARS-CoV-2 coronavirus proteins are freely available from the RCSB Protein Data Bank headquartered at Rutgers University–New Brunswick. The data bank reached the milestone this week, with 1,018 proteins as…
As large multi-cancer datasets become more important for predicting who may benefit from cancer drugs, a new model better accounts for potentially overlooked variation.
A lab on UNLV’s campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery — one that could potentially provide a solution for patients who have run out of options.
ORNL story tips: Modeling COVID, permafrost lost and taking the heat
The February edition of SLAS Technology is a special collection of articles focused on “Artificial Intelligence in Process Automation” by Guest Editor Cenk Ündey, Ph.D. (Amgen, Thousand Oaks, CA, USA).
The February edition of SLAS Discovery is a Special Issue on Hit Discovery Methodologies edited by Mark Wigglesworth, Ph.D., (Medicines Discovery Catapult, Stockport, EN, UK) and Peter Hodder, Ph.D. (Amgen, Thousand Oaks, CA, USA).
Two students working under the mentorship of Desigan Kumaran, a structural biologist at the U.S. Department of Energy’s Brookhaven National Laboratory, have helped to identify molecules that could potentially lead to new antiviral drugs for treating COVID-19. Though the students conducted their fall 2020 internships remotely, the potential of their work is firmly planted in the real world and could have lasting impact.
The January edition of SLAS Discovery features the cover article, “Cryo-EM: The Resolution Revolution and Drug Discovery” by Taiana Maia de Oliveira, Ph.D., Lotte van Beek, Ph.D., Fiona Shilliday, Ph.D., Judit E. Debreczeni, Ph.D., and Chris Phillips, Ph.D., from AstraZeneca.
The PhRMA Foundation announced the first recipients of its new funding awards in Drug Discovery and Drug Delivery, designed to support the innovative biopharmaceutical research projects of talented young scientists in the United States. A total of 16 recipients were selected and more than $1 million was awarded.
the National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant at the University of Delaware. The COBRE research team is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn’s disease, tuberculosis and Legionnaires disease.
New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.
The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.
A machine learning model developed by a team of Lawrence Livermore National Laboratory (LLNL) scientists to aid in COVID-19 drug discovery efforts is a finalist for the Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research.
“There’s no place like home,” has its roots deep in the brain. Using fiber photometry, scientists are the first to show that home evokes a surge of dopamine in mice that mimics the response to a dose of cocaine. The study demonstrates how dopamine rises rapidly in mice moved from a simple recording chamber to their home cage, but less so when they return to a cage not quite like the one they knew.
Using 3-D cell culture, researchers identify a promising drug lead against a bladder cancer subtype
Lawrence Livermore National Laboratory and its partners AMD, Supermicro and Cornelis Networks have installed a new high performance computing (HPC) cluster with memory and data storage capabilities optimized for data-intensive COVID-19 research and pandemic response.
Anyone with a smartphone can download the app ViDok, which lets users pick from a library of molecules that might bind to key proteins on the SARS-CoV-2 virus, which causes COVID-19, and then can tweak the molecules to try to find a better fit.
The drug discovery program is focused on the assessment of hundreds of drug candidates in the CDI labs, to find the most promising potential therapies.
Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are making progress on several fronts in the battle against COVID-19, the global pandemic sparked by the emergence of a novel coronavirus late last year. This work is part of a worldwide effort to understand the virus and the factors that affect its spread with the aim of devising treatments and other mitigation strategies.
With funding from the Coronavirus Aid, Relief and Economic Security (CARES) Act, Lawrence Livermore National Laboratory, chipmaker AMD and information technology company Supermicro have upgraded the supercomputing cluster Corona, providing additional resources to scientists for COVID-19 drug discovery and vaccine research
Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries. The findings, which were published today in Nature Cell Biology, could lead to better therapies for patients with lung disease, including acute respiratory distress syndrome (ARDS) due to COVID-19.
High school summer students at Brookhaven Lab conduct computational studies, explore inhibitor drugs to disrupt COVID viral proteins that help infectious particles escape from cells.
When the COVID-19 pandemic hit, many students had to rejigger summer plans. Internships they’d expected to be in-person moved to all-virtual formats. For more than 30 students participating in virtual summer programs at the Brookhaven Lab, that disruption presented an opportunity—a chance to engage in research related to the virus responsible for the upheaval.
Structural biology techniques helped researchers target the nuclear receptor-binding SET domain family for the first time; its malfunction is associated with several types of cancer.
A new program in Biotechnology and Health Economics at Rensselaer Polytechnic Institute will equip students destined for a science-based career with the quantitative and modeling knowledge in economics needed to succeed in industry and consulting.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, a type of aggressive brain tumor.
Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. The research is the latest example of a decoy strategy researchers at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis. It could speed discovery of anti-TB drugs and be applied to other pathogens.
Researchers have developed a new drug that prevents blood clots without causing an increased risk of bleeding, a common side effect of all antiplatelet medications currently available. A new study published in the journal Science Translational Medicine describes the drug and its delivery mechanisms and shows that the drug is also an effective treatment for heart attack in animal models.
The CDI will work with Merck to identify candidate treatments for the still-spreading pandemic.
At a glance:
• Scientists develop AI-based tool to predict adverse drug events
• Such events are responsible for some 2 million U.S. hospitalizations per year
• The free, open-source system could enable safer drug design, optimize drug safety
A team of scientists led by Abhishek Singharoy at Arizona State University used the Summit supercomputer at the Oak Ridge Leadership Computing Facility to simulate the structure of a possible drug target for the bacterium that causes rabbit fever.
University of Alabama in Huntsville (UAH) professor of biological science Dr. Jerome Baudry is collaborating with Hewlett Packard Enterprise (HPE) to use HPE’s Cray Sentinel supercomputer to search for natural products that are effective against the COVID-19 virus.
Fermilab, Brookhaven, and Open Science Grid dedicate computational power to COVID-19 research.
A new, free-to-use database of 14,000 known macrolactones fills a knowledge gap concerning these molecules and could serve as a useful tool for future drug discovery.
A team of scientists has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.
The discovery marks a critical step toward developing a potential new class of anti-cancer drugs that enhance the activity of a prevalent family of tumor suppressor proteins.
A team of Stony Brook University (SBU) researchers is working on computer models that could help speed the discovery of drugs to combat the novel coronavirus responsible for COVID-19. They are doing this work in collaboration with scientists at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory and Argonne National Laboratory, and will be leveraging those laboratories’ computational resources and expertise.